Assembly Biosciences (ASMB) Current Deferred Tax Assets (2017)

Assembly Biosciences' (ASMB) quarterly Current Deferred Tax Assets came in at $4.9 million in Q4 2017.

Assembly Biosciences (ASMB) Current Deferred Tax Assets (2017) Analysis & Trends

Assembly Biosciences' Current Deferred Tax Assets history runs 1 years deep, the most recent figure standing at $4.9 million for Q4 2017.

On a quarterly basis, Current Deferred Tax Assets changed N/A year-over-year to $4.9 million in Q4 2017; TTM through Dec 2017 was $4.9 million, a N/A change from a year earlier, with the FY2017 full-year figure at $4.9 million, changed N/A from the prior year.
Current Deferred Tax Assets held at $4.9 million in Q4 2017 per ASMB's latest filing.
Across five years, Current Deferred Tax Assets topped out at $4.9 million in Q4 2017 and bottomed at $4.9 million in Q4 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Assembly Biosciences	282.74 Mn	56.14 Mn	-

Download Data

Date	Value
Dec 31, 2017	4.90 Mn
Dec 31, 2017	4.90 Mn